Clinical Trials Logo

Coronary Artery Disease clinical trials

View clinical trials related to Coronary Artery Disease.

Filter by:
  • Terminated  
  • Page 1 ·  Next »

NCT ID: NCT03488654 Terminated - Clinical trials for Coronary Artery Disease

CMR-Lupus Comprehensive Approach by Cardiovascular Magnetic Resonance Tomography

Start date: July 2010
Study type: Observational

In systemic lupus erythematosus (SLE), cardiac manifestations, e.g. coronary artery disease (CAD) and myocarditis are leading causes of morbidity and mortality. The prevalence of subclinical heart disease in SLE is unknown. We studied whether a comprehensive cardiovascular magnetic resonance (CMR) protocol may be useful for early diagnosis of heart disease in SLE patients without known CAD

NCT ID: NCT03184805 Terminated - Clinical trials for Coronary Artery Disease

STOPping Versus Continuing Antiplatelet Therapy During Noncardiac Surgery and Procedures After Next Generation Drug-eluting Stent Implantation

Start date: June 23, 2017
Phase: N/A
Study type: Interventional

Most previous trials support the absolute increase in bleeding risk with perioperative administration of antiplatelet. Furthermore, recent studies demonstrated that perioperative major bleeding may be related to increase cardiovascular risk. The investigators will compare the efficacy and safety of continuing versus stopping antiplatelet therapy during perioperative period in patients underwent PCI(Percutaneous Coronary Intervention) with next generation DES(Drug Eluting Stent).

NCT ID: NCT02915991 Terminated - Clinical trials for Coronary Artery Disease

User Evaluation Study of SyncVision System With Software v4.X

Prepare II
Start date: November 2016
Study type: Observational

This is a prospective, single-arm, unblinded, case observation study evaluating a commercially released 'Conformité Européenne' (CE)-mark co-registration software system along-side of a commercially- released CE-mark coronary physiology and X-ray system during routine clinical workflow. The purpose of this study is to collect Professional user feedback regarding clinical utility of the SyncVision 4.X system.

NCT ID: NCT02831205 Terminated - Clinical trials for Percutaneous Transluminal Coronary Angioplasty

Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Metallic Stents for Diffuse Long Coronary Artery Disease

Start date: July 2016
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine whether ABSORB bioresorbable vascular scaffold is non-inferior to XIENCE everolimus-eluting cobalt-chromium stent with respect to target-lesion failure (TLF) at 1 year.

NCT ID: NCT02739685 Terminated - Clinical trials for Coronary Artery Disease

Bioresorbable Vascular Scaffolds Versus Stents in Patients With Chronic Total Occlusion

Start date: September 2016
Phase: Phase 4
Study type: Interventional

The purpose of the current study is to demonstrate non-inferiority of everolimus-eluting bioresorbable vascular scaffold to everolimus-eluting stents in patients with chronic total occlusion regarding the antirestenotic efficacy at 8 to 10-month angiographic follow-up.

NCT ID: NCT02699671 Terminated - Clinical trials for Coronary Artery Disease


Start date: June 2016
Phase: N/A
Study type: Observational

The purpose of this study is to evaluate the relative effectiveness and safety of Bioresorbable Vascular Scaffold in acute myocardial infarction compared to other (drug eluting stents) DES.

NCT ID: NCT02694016 Terminated - Myocardial Ischemia Clinical Trials

Remote Ischemic Preconditioning in Patients Undergoing Isolated Aortic Valve Replacement Surgery

Start date: February 2016
Phase: N/A
Study type: Interventional

The goal is to investigate the efficacy, safety and possible neuro- and cardioprotective effects of remote ischemic preconditioning (RIPC) in adult cardiac patients undergoing isolated aortic valve replacement surgery with a biological prosthesis. Neuropsychological evaluation preoperatively and at 30d after surgery will establish if there are any differences in neuropsychological performance between groups. A large array of biochemical markers will be analyzed from plasma samples taken at different time points. Additionally skin biopsies from the lower limb will be taken before and after performing RIPC on said limb. During the venous cannulation phase a atrial biopsy will be taken. The biochemical markers from plasma and tissue samples will be used to asses brain tissue damage, inflammation and cardiac tissue damage between groups. This will be a single center prospective randomized study with two groups. A intervention group (RIPC) and a control group. Study size is: 40 patients in total, 20 patients per group.

NCT ID: NCT02632292 Terminated - Clinical trials for Coronary Artery Disease

EverolimuS-ElUtinG BioresorbAble VasculaR Scaffolds vErsus EVerolimus-Eluting Stents in Patients With Diabetes Mellitus

Start date: January 2016
Phase: Phase 4
Study type: Interventional

Prospective, randomized, controlled, multicenter, open-label study to compare everolimus-eluting bioresorbable vascular scaffolds to everolimus-eluting stents in patients with diabetes mellitus.

NCT ID: NCT02611050 Terminated - Clinical trials for Coronary Artery Disease

Treatment Decisions for Multi-vessel CAD

Start date: September 20, 2015
Phase: N/A
Study type: Interventional

This study is a multi-center randomized trial to evaluate the Multi-vessel Coronary Artery Disease Option Grid patient decision aid compared to usual care in patient reported decisional conflict, knowledge, and shared decision making.

NCT ID: NCT02601664 Terminated - Clinical trials for Coronary Artery Disease

Randomized-controlled Trial of a Combined vs. Conventional Percutaneous Intervention for Near-Infrared Spectroscopy Defined High-Risk Native Coronary Artery Lesions

Start date: November 2015
Phase: Phase 4
Study type: Interventional

Design: Single center, single-blind randomized controlled trial of patients with high risk native coronary artery lesions (defined as ≥2 contiguous yellow blocks on the block chemogram) requiring clinically indicated percutaneous coronary intervention. Patients will be randomized to either a combined intervention or conventional PCI. Cardiac biomarker measurements will be performed before PCI and 18-24 hours later. Treatment: Combined intervention consisting of pre-PCI intracoronary vasodilator and glycoprotein IIb/IIIa inhibitor administration, use of an EPD if technically feasible, and complete coverage of the lipid core plaque, if technically feasible. Control: Conventional PCI. Duration: 30 days follow-up. The primary trial objective is to compare the incidence and size of periprocedural MI, as assessed by the peak post-PCI troponin distribution in the two study groups. The secondary endpoints are: (1) Reduction in the incidence of >3x and >10x upper limit of normal increase in CK-MB. (2) Reduction in the incidence of slow flow/no-reflow post PCI. (3) Lower incidence of major adverse cardiac events, defined as the composite of death, acute coronary syndrome, or coronary revascularization) during 30-day follow-up.